BENEFITS
The main difference, compared to other docetaxel formulations, is that Docetaxel Injection is the first non-alcohol formulation approved in the U.S. Further differentiating it from some of the currently marketed docetaxel formulations is that Teikoku’s Docetaxel Injection:
- Requires no prior dilution with a diluent and is ready to add to the infusion solution
- Is available in three presentations: 20mg/ml in single-dose vials, and 80 mg/4 mL or 160 mg/8 mL in multiple-dose vials.
CONTACT US
Contact us for distribution or licensing opportunities, or to learn more about our growing portfolio of life-changing drug therapies.
"*" indicates required fields